BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trotz M, Wegner C, Nau H. Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouse. Life Sciences 1987;41:103-10. [DOI: 10.1016/0024-3205(87)90562-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bower C, Stanley F. The role of nutritional factors in the aetiology of neural tube defects. J Paediatr Child Health 1992;28:12-6. [PMID: 1554510 DOI: 10.1111/j.1440-1754.1992.tb02610.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
2 Nau H, Hauck RS, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991;69:310-21. [PMID: 1803343 DOI: 10.1111/j.1600-0773.1991.tb01303.x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 188] [Article Influence: 7.0] [Reference Citation Analysis]
3 Nau H, Siemes H. Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity: Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as Δ2-valproate. Pharmaceutisch Weekblad Scientific Edition 1992;14:101-7. [DOI: 10.1007/bf01962697] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Wiltse J. Mode of Action: Inhibition of Histone Deacetylase, Altering WNT-Dependent Gene Expression, and Regulation of Beta-Catenin—Developmental Effects of Valproic Acid. Critical Reviews in Toxicology 2008;35:727-38. [DOI: 10.1080/10408440591007403] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
5 Yerby MS. Pregnancy, Teratogenesis, and Epilepsy. Neurologic Clinics 1994;12:749-71. [DOI: 10.1016/s0733-8619(18)30075-6] [Cited by in Crossref: 57] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gossrau R, Graf R. Lesions and repair of cells of maternal mice after valproic acid (VPA) treatment on day 8 of pregnancy: An enzyme histochemical analysis. Acta Histochemica 1989;86:23-32. [DOI: 10.1016/s0065-1281(89)80042-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Greene ND, Copp AJ. Mouse models of neural tube defects: investigating preventive mechanisms. Am J Med Genet C Semin Med Genet 2005;135C:31-41. [PMID: 15800852 DOI: 10.1002/ajmg.c.30051] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
8 Watterson JM, Watson DG, Meyer EM, Lenox RH. A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity. Brain Res 2002;934:69-80. [PMID: 11937071 DOI: 10.1016/s0006-8993(02)02362-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 DeSesso JM, Scialli AR, Holson JF. Apparent lability of neural tube closure in laboratory animals and humans. Am J Med Genet 1999;87:143-62. [PMID: 10533029 DOI: 10.1002/(sici)1096-8628(19991119)87:2<143::aid-ajmg6>3.0.co;2-j] [Cited by in Crossref: 43] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
10 Fleming A. The Role of Folate in the Prevention of Neural Tube Defects: Human and Animal Studies. Nutrition Reviews 2001;59:S13-23. [DOI: 10.1111/j.1753-4887.2001.tb05497.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD. Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 1997;70:303-11. [DOI: 10.1002/(sici)1096-8628(19970613)70:3<303::aid-ajmg17>3.0.co;2-p] [Cited by in Crossref: 38] [Article Influence: 1.5] [Reference Citation Analysis]
12 Hansen DK. In vitro effects of folate derivatives on valproate-induced neural tube defects in mouse and rat embryos. Toxicol In Vitro 1993;7:735-42. [PMID: 20732274 DOI: 10.1016/0887-2333(93)90075-g] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Lucock MD, Hartley R, Smithells RW. A rapid and specific HPLC-electrochemical method for the determination of endogenous 5-methyltetrahydrofolic acid in plasma using solid phase sample preparation with internal standardization. Biomed Chromatogr 1989;3:58-63. [DOI: 10.1002/bmc.1130030204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
14 Wegner C, Drews E, Nau H. Zinc concentrations in mouse embryo and maternal plasma: Effect of valproic acid and a nonteratogenic metabolite. Biol Trace Elem Res 1990;25:211-7. [DOI: 10.1007/bf02990416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Jergil M, Kultima K, Gustafson AL, Dencker L, Stigson M. Valproic acid-induced deregulation in vitro of genes associated in vivo with neural tube defects. Toxicol Sci 2009;108:132-48. [PMID: 19136453 DOI: 10.1093/toxsci/kfp002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
16 Padmanabhan R, Ahmed I. Sodium valproate augments spontaneous neural tube defects and axial skeletal malformations into mouse fetuses. Reproductive Toxicology 1996;10:345-63. [DOI: 10.1016/0890-6238(96)00081-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 0.9] [Reference Citation Analysis]
17 Hansen D, Dial S, Grafton T. Lack of attenuation of valproic acid-induced embryotoxicity by compounds involved in one-carbon transfer reactions. Toxicology in Vitro 1995;9:615-21. [DOI: 10.1016/0887-2333(95)91009-q] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Nau H, Lewandowski C, Klug S, Neubert D. Pharmacokinetic aspects of drug effects in vitro (II) placental transfer to the embryo and activity of some carboxylic acids structurally related to valproic acid in whole embryos in culture. Toxicology in Vitro 1988;2:169-74. [DOI: 10.1016/0887-2333(88)90004-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
19 Hansen DK, Grafton TF, Dial SL, Gehring TA, Siitonen PH. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 1995;52:277-85. [PMID: 8838251 DOI: 10.1002/tera.1420520506] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
20 Nau H. Valproic acid-induced neural tube defects. Ciba Found Symp 1994;181:144-52; discussion 152-60. [PMID: 8005022 DOI: 10.1002/9780470514559.ch9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
21 Moore JL. The significance of folic acid for epilepsy patients. Epilepsy & Behavior 2005;7:172-81. [DOI: 10.1016/j.yebeh.2005.05.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
22 Mullin RJ, Keith BR, Duch DS. Distribution and Metabolism of Calcium Leucovorin in Normal and Tumor Tissue. In: Rustum Y, Mcguire JJ, editors. The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. New York: Springer US; 1988. pp. 25-38. [DOI: 10.1007/978-1-4684-5607-3_3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
23 Malek FA, Möritz KU, Fanghänel J, Bienengräber V. Reduction of procarbazine-induced cleft palates by prenatal folic acid supplementation in rats. Pathol Res Pract 2004;200:33-40. [PMID: 15157048 DOI: 10.1016/j.prp.2003.12.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
24 Padmanabhan R, Abdulrazzaq YM, Bastaki SMA. Valproic acid-induced congenital malformations: Clinical and experimental observations. Congenital Anomalies 2000;40:259-68. [DOI: 10.1111/j.1741-4520.2000.tb00923.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
25 Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain: an economic analysis. Am J Public Health 1995;85:667-76. [PMID: 7733427 DOI: 10.2105/ajph.85.5.667] [Cited by in Crossref: 68] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
26 Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 2003;43:29-40. [PMID: 12692401 DOI: 10.1111/j.1741-4520.2003.tb01024.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
27 Wegner C, Nau H. Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. Reproductive Toxicology 1991;5:465-71. [DOI: 10.1016/0890-6238(91)90017-a] [Cited by in Crossref: 47] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Copp AJ, Brook FA, Estibeiro JP, Shum AS, Cockroft DL. The embryonic development of mammalian neural tube defects. Prog Neurobiol. 1990;35:363-403. [PMID: 2263736 DOI: 10.1016/0301-0082(90)90037-h] [Cited by in Crossref: 227] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
29 Gardner NM, Riley RT, Showker JL, Voss KA, Sachs AJ, Maddox JR, Gelineau-van Waes JB. Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects. Toxicol Sci 2016;150:161-8. [PMID: 26719367 DOI: 10.1093/toxsci/kfv321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
30 Ehlers K, Stürje H, Merker H, Nau H. Valproic acid-induced spina bifida: A mouse model. Teratology 1992;45:145-54. [DOI: 10.1002/tera.1420450208] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 3.5] [Reference Citation Analysis]
31 Hauck R, Nau H. Zu den strukturellen Grundlagen der teratogenen Wirkung des Antiepileptikums Valproinsäure (VPA): 2-n-Propyl-4-pentinsäure, das erste Strukturanalogon mit signifikant höherer teratogener Aktivität als VPA. Naturwissenschaften 1989;76:528-9. [DOI: 10.1007/bf00374130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Finnell RH. Genetic Differences in Susceptibility to Anticonvulsant Drug-Induced Developmental Defects. Pharmacology & Toxicology 1991;69:223-7. [DOI: 10.1111/bcpt.1991.69.4.223] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
33 Jentink J, Bakker MK, Nijenhuis CM, Wilffert B, de Jong-van den Berg LT. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf 2010;19:803-7. [PMID: 20680999 DOI: 10.1002/pds.1975] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
34 Dencker L, Nau H, D'Argy R. Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis. Teratology 1990;41:699-706. [PMID: 2353317 DOI: 10.1002/tera.1420410606] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 1.2] [Reference Citation Analysis]
35 Hauck RS, Nau H. The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice. Pharm Res 1992;9:850-5. [PMID: 1437995 DOI: 10.1023/a:1015832411981] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Spiegelstein O, Merriweather MY, Wicker NJ, Finnell RH. Valproate-induced neural tube defects in folate-binding protein-2 (Folbp2) knockout mice. Birth Defect Res A 2003;67:974-8. [DOI: 10.1002/bdra.10128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
37 Dodson WE. Deleterious Effects of Drugs on the Developing Nervous System. Clinics in Perinatology 1989;16:339-60. [DOI: 10.1016/s0095-5108(18)30636-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
38 Berking S. Effects of the anticonvulsant drug valproic acid and related substances on developmental processes in hydroids. Toxicology in Vitro 1991;5:109-17. [DOI: 10.1016/0887-2333(91)90030-h] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Fuller LC, Cornelius SK, Murphy CW, Wiens DJ. Neural crest cell motility in valproic acid. Reproductive Toxicology 2002;16:825-39. [DOI: 10.1016/s0890-6238(02)00059-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
40 Hansen DK, Grafton TF. Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro. Teratology 1991;43:575-82. [DOI: 10.1002/tera.1420430612] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 1.2] [Reference Citation Analysis]
41 Radatz M, Nau H. Toxicity. In: Löscher W, editor. Valproate. Basel: Birkhäuser; 1999. pp. 91-128. [DOI: 10.1007/978-3-0348-8759-5_5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
42 Finnell RH, Gelineau-van Waes J, Bennett GD, Barber RC, Wlodarczyk B, Shaw GM, Lammer EJ, Piedrahita JA, Eberwine JH. Genetic basis of susceptibility to environmentally induced neural tube defects. Ann N Y Acad Sci 2000;919:261-77. [PMID: 11083116 DOI: 10.1111/j.1749-6632.2000.tb06886.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
43 Shan L, Fan Y, Li H, Liu W, Gu H, Zhou F, Yuan Z. Proteomic analysis of amniotic fluid of pregnant rats with spina bifida aperta. J Proteomics 2012;75:1181-9. [PMID: 22108047 DOI: 10.1016/j.jprot.2011.10.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
44 Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discovery Today 2009;14:428-35. [DOI: 10.1016/j.drudis.2009.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
45 ten Berg K, van Oppen ACC, Nikkels PGJ, Gittenberger-de Groot AC, van der Voet GB, Brilstra EH, Lindhout D. Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure. Prenat Diagn 2005;25:156-8. [DOI: 10.1002/pd.1098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Elmazar MMA, Nau H. Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. Teratog Carcinog Mutagen 1992;12:203-10. [DOI: 10.1002/tcm.1770120503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid. Ann Pharmacother 1998;32:947-61. [PMID: 9762383 DOI: 10.1345/aph.17298] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
48 Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reproductive Toxicology 1991;5:281-99. [DOI: 10.1016/0890-6238(91)90090-3] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 2.4] [Reference Citation Analysis]
49 Paros A, Beck SL. Folinic acid reduces cleft lip [CL(P)] in A/WySn mice. Teratology 1999;60:344-7. [PMID: 10590395 DOI: 10.1002/(SICI)1096-9926(199912)60:6<344::AID-TERA6>3.0.CO;2-M] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
50 Briner W. The effect of GABA receptor ligands in experimental spina bifida occulta. BMC Pharmacol 2001;1:2. [PMID: 11532198 DOI: 10.1186/1471-2210-1-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
51 Swaab DF, Boer GJ, Feenstra MG. Concept of functional neuroteratology and the importance of neurochemistry. Biochemical Basis of Functional Neuroteratology - Permanent Effects of Chemicals on the Developing Brain. Elsevier; 1988. pp. 3-14. [DOI: 10.1016/s0079-6123(08)60493-8] [Cited by in Crossref: 12] [Article Influence: 0.4] [Reference Citation Analysis]
52 Finnell RH, Caiaffa CD, Kim SE, Lei Y, Steele J, Cao X, Tukeman G, Lin YL, Cabrera RM, Wlodarczyk BJ. Gene Environment Interactions in the Etiology of Neural Tube Defects. Front Genet 2021;12:659612. [PMID: 34040637 DOI: 10.3389/fgene.2021.659612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lucock M, Wild J, Smithells R, Hartley R. In vivo characterization of the absorption and biotransformation of pteroylmonoglutamic acid in man: A model for future studies. Biochemical Medicine and Metabolic Biology 1989;42:30-42. [DOI: 10.1016/0885-4505(89)90038-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.1] [Reference Citation Analysis]
54 Lindhout D, Omtzigt JGC. Pregnancy and the Risk of Teratogenicity. Epilepsia 1992;33:41-8. [DOI: 10.1111/j.1528-1157.1992.tb06226.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 2.3] [Reference Citation Analysis]
55 Nau H. Pharmakokinetische Grundlagen der Teratogenität von Arzneimitteln. In: Buchborn E, Classen M, Dölle W, Gross R, van de Loo J, Riecker G, Scriba PC, Siegenthaler W, von Wichert P, editors. Der Internist. Berlin: Springer Berlin Heidelberg; 1988. pp. 179-92. [DOI: 10.1007/978-3-662-39609-4_25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Kappen C, Mello MA, Finnell RH, Salbaum JM. Folate modulates Hox gene-controlled skeletal phenotypes. Genesis 2004;39:155-66. [PMID: 15282741 DOI: 10.1002/gene.20036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
57 Nau H. Experimentelle Studien zur Teratogenität von Valproinsäure. In: Krämer G, Laub MC, editors. Valproinsäure. Berlin: Springer Berlin Heidelberg; 1992. pp. 289-97. [DOI: 10.1007/978-3-642-97843-2_30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
58 Lindhout D, Omtzigt JGC. Teratogenic Effects of Antiepileptic Drugs: Implications for the Management of Epilepsy in Women of Childbearing Age. Epilepsia 1994;35:S19-28. [DOI: 10.1111/j.1528-1157.1994.tb05952.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 2.8] [Reference Citation Analysis]
59 Manning SM, Jennings R, Madsen JR. Pathophysiology, prevention, and potential treatment of neural tube defects. Ment Retard Dev Disabil Res Rev 2000;6:6-14. [PMID: 10899792 DOI: 10.1002/(SICI)1098-2779(2000)6:1<6::AID-MRDD2>3.0.CO;2-B] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
60 Copp AJ. Neural tube defects. Trends in Neurosciences 1993;16:381-3. [DOI: 10.1016/0166-2236(93)90001-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
61 Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M. Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defect Res B 2004;71:47-53. [DOI: 10.1002/bdrb.10057] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
62 Cotariu D, Zaidman J. Developmental toxicity of valproic acid. Life Sciences 1991;48:1341-50. [DOI: 10.1016/0024-3205(91)90430-j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Finnell RH, Bielec B, Nau H. Anticonvulsant Drugs: Mechanisms and Pathogenesis of Teratogenicity. In: Kavlock RJ, Daston GP, editors. Drug Toxicity in Embryonic Development II. Berlin: Springer Berlin Heidelberg; 1997. pp. 121-59. [DOI: 10.1007/978-3-642-60447-8_3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
64 Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999;8:253-4. [DOI: 10.1053/seiz.1999.0283] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
65 Elmazar MM, Nau H. Trimethoprim potentiates valproic acid-induced Neural Tube Defects (NTDs) in mice. Reproductive Toxicology 1993;7:249-54. [DOI: 10.1016/0890-6238(93)90231-u] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]